Cystic Fibrosis: Much More Than a Pulmonary Disease

Cystic fibrosis is a systemic secretory disease, not just a lung problem, and adults with CF now present to the ED with both pulmonary exacerbations and end-organ complications. Pulmonary decline still drives most visits, but pneumothorax, hemoptysis, cor pulmonale, pancreatic insufficiency, and biliary disease all change emergency management.

Cystic Fibrosis in the ED

• Systemic secretory disease: CFTR dysfunction dehydrates secretions across the lungs, pancreas, intestines, biliary tree, and sweat glands, making cystic fibrosis a multi-organ disease rather than an isolated pulmonary diagnosis.
• Pulmonary exacerbation pattern: Pulmonary exacerbations drive most ED presentations and typically show increasing dyspnea, tachypnea, hypoxia, sputum change, and worsening adventitious sounds on top of chronic productive cough.
• Patient-guided management: Many patients with CF know their baseline regimen, prior culture history, and which airway-clearance therapies help them most; that shared decision-making matters in the ED, and we get into the bedside approach in the episode.
• Imaging first principles: Chest radiography is the default first study in a suspected exacerbation, with hyperinflation often appearing early; compare with prior films to separate chronic bronchiectatic change from new pathology.
• COPD-like initial care: Initial treatment parallels COPD exacerbation care with oxygen support, bronchodilators, and secretion management, but airway clearance is central and anticholinergics may outperform beta-agonists in some patients.
• Culture-directed antibiotics: Pseudomonas aeruginosa is the signature pathogen and chronic colonization is common, so sputum cultures and prior microbiology should guide therapy rather than assuming a new organism each time.

Complications Beyond Pulmonary Exacerbation

• Pneumothorax risk rises: Pneumothorax becomes more common with age in CF, often from ruptured subpleural blebs, and pleural interventions can complicate future lung transplant planning.
• Hemoptysis warning sign: Hemoptysis reflects bronchiectatic airway injury and inflammatory angiogenesis; most cases are self-limited, but severe bleeding may require bronchial artery embolization or surgery.
• ABPA and wheezing: Marked wheezing in CF is not always a routine exacerbation; allergic bronchopulmonary aspergillosis is a key alternate diagnosis even though Aspergillus isolation alone is common.
• Right heart failure clues: Advanced pulmonary disease can progress to pulmonary hypertension and cor pulmonale, with tender hepatomegaly and ascites serving as useful bedside clues during a hypoxic decompensation.
• Pancreatic and biliary disease: Pancreatic insufficiency starts early, and liver disease is a major cause of death in CF, so elevated transaminases, gallstones, portal hypertension, and variceal bleeding all belong on the ED differential.

References:

1. Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009;180(9):802-808. PMID: 19729669
2. Grossheim, L. Gates, K. Emergency Department Care of Cystic Fibrosis Patients. Emergency  Medicine Reports. https://www.reliasmedia.com/articles/11691-emergency-department care-of-adult-cystic-fibrosis-patientsPublished online: April 27, 2008.
3. Hassan M, Bonafede MM, Limone BL, Hodgkins P, Sawicki GS. The burden of cystic fibrosis in the Medicaid population. Clinicoecon Outcomes Res. 2018;10:423-431. Published 2018 Jul 25. PMID: 30100747